معرفی
Marco Mor is a Full Professor of Medicinal Chemistry at the University of Parma and a leading researcher in drug design and enzyme inhibition. His work spans computational modeling, synthetic chemistry, and pharmacokinetic studies, focusing on endocannabinoid modulators and melatonin receptor ligands. He has coordinated major projects like ONCOPENTA and the national PRIN initiative ExECS, and serves as Director of the PhD School in Biological, Pharmaceutical, and Food Sciences at the University of Parma.
- Education: Laurea (M.S.) in Pharmaceutical Chemistry and Technology, University of Parma (1990).
- Appointments: Lecturer (1993), Associate Professor (2000), Full Professor (2001–present).
His research group integrates molecular modeling, synthetic chemistry, and analytical methods to develop novel pharmacological agents targeting enzymes like FAAH, MGL, and NAAA. Key contributions include the design of the FAAH inhibitor URB597 and its derivatives, as well as MT2-selective melatonin agonists for sleep disorders. Current work explores covalent EGFR inhibitors with reduced toxicity and gut microbiome interactions in drug metabolism.
Recent publications highlight his interdisciplinary approach, covering topics from histone deacetylase inhibitors for fibrosis to microbiome-genome interactions in probiotic characterization. Collaborations with international teams on projects like the Integrated Probiotic Database and MEGAnnotator2 genome pipeline reflect his broad scientific impact.
